Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

English version České info

John Mascola and colleagues study the safety and pharmacokinetics of VRC01LS, a broadly neutralizing anti-HIV-1 antibody designed to have an extended half-life in serum, in healthy people.

Vyšlo v časopise: Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med 15(1): e32767. doi:10.1371/journal.pmed.1002493
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002493

Souhrn

John Mascola and colleagues study the safety and pharmacokinetics of VRC01LS, a broadly neutralizing anti-HIV-1 antibody designed to have an extended half-life in serum, in healthy people.

Zdroje

1. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. 2013;254(1):225–44. Epub 2013/06/19. PubMed Central PMCID: PMC3738265. doi: 10.1111/imr.12075 23772623

2. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;275(1):33–48. Epub 2017/01/31. doi: 10.1111/imr.12502 28133792; PubMed Central PMCID: PMC5300048.

3. McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 2017;275(1):11–20. Epub 2017/01/31. doi: 10.1111/imr.12484 28133814; PubMed Central PMCID: PMC5299474.

4. Wibmer CK, Moore PL, Morris L. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015;10(3):135–43. doi: 10.1097/COH.0000000000000153 25760932; PubMed Central PMCID: PMC4437463.

5. Julien JP, Lee PS, Wilson IA. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev. 2012;250(1):180–98. Epub 2012/10/11. doi: 10.1111/imr.12005 23046130; PubMed Central PMCID: PMC3479221.

6. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289–301. Epub 2015/09/04. doi: 10.1111/cei.12692 26332605; PubMed Central PMCID: PMC4636891.

7. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206. Epub 2015/12/25. doi: 10.1126/scitranslmed.aad5752 26702094.

8. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–91. Epub 2015/04/10. doi: 10.1038/nature14411 25855300; PubMed Central PMCID: PMC4890714.

9. Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185–91. Epub 2017/01/17. doi: 10.1038/nm.4268 28092665; PubMed Central PMCID: PMC5467219.

10. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13(9):693–701. doi: 10.1038/nri3516 23969737.

11. Pegu A, Hessell AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev. 2017;275(1):296–312. Epub 2017/01/31. doi: 10.1111/imr.12511 28133803; PubMed Central PMCID: PMC5314445.

12. Caskey M, Klein F, Nussenzweig MC. Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. N Engl J Med. 2016;375(21):2019–21. doi: 10.1056/NEJMp1613362 27959740.

13. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37(3):412–25. Epub 2012/09/25. doi: 10.1016/j.immuni.2012.08.012 22999947; PubMed Central PMCID: PMC4706166.

14. Ward ES, Ober RJ. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol. 2009;103:77–115. Epub 2009/09/17. doi: 10.1016/S0065-2776(09)03004-1 19755184; PubMed Central PMCID: PMC4485553.

15. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. doi: 10.1126/science.1192819 20616231; PubMed Central PMCID: PMC2981354.

16. West AP Jr., Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A. 2012;109(30):E2083–90. doi: 10.1073/pnas.1208984109 22745174; PubMed Central PMCID: PMC3409792.

17. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. doi: 10.1126/science.1187659 20616233; PubMed Central PMCID: PMC2965066.

18. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016;12(3):e1005520. Epub 2016/03/31. doi: 10.1371/journal.ppat.1005520 27028935; PubMed Central PMCID: PMC4814126.

19. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–30. doi: 10.4161/mabs.3.5.16983 22048693; PubMed Central PMCID: PMC3225846.

20. Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol. 2015;67(2 Pt A):131–41. doi: 10.1016/j.molimm.2015.02.007 25766596; PubMed Central PMCID: PMC4529761.

21. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591–604. Epub 2000/11/30. doi: 10.1074/jbc.M009483200 11096108.

22. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18(12):1759–69. Epub 2006/11/02. doi: 10.1093/intimm/dxl110 17077181.

23. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279(8):6213–6. Epub 2003/12/31. doi: 10.1074/jbc.C300470200 14699147.

24. Kamei DT, Lao BJ, Ricci MS, Deshpande R, Xu H, Tidor B, et al. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol Bioeng. 2005;92(6):748–60. Epub 2005/09/02. doi: 10.1002/bit.20624 16136591.

25. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8. Epub 2005/09/28. doi: 10.1038/nbt1143 16186811.

26. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24. Epub 2006/06/24. doi: 10.1074/jbc.M604292200 16793771.

27. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176(1):346–56. Epub 2005/12/21. PubMed 16365427.

28. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi: 10.1128/AAC.01285-13 24080653; PubMed Central PMCID: PMC3837853.

29. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388). Epub 2017/05/05. doi: 10.1126/scitranslmed.aaj1928 28469033.

30. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514(7524):642–5. doi: 10.1038/nature13612 25119033; PubMed Central PMCID: PMC4433741.

31. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–9. doi: 10.1038/nbt.1601 20081867; PubMed Central PMCID: PMC2855492.

32. Pandey JP, Namboodiri AM, Mohan S, Nietert PJ, Peterson L. Genetic markers of immunoglobulin G and immunity to cytomegalovirus in patients with breast cancer. Cell Immunol. 2017;312:67–70. Epub 2016/11/09. doi: 10.1016/j.cellimm.2016.11.003 27825564; PubMed Central PMCID: PMC5290197.

33. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. doi: 10.1016/j.jim.2013.11.022 24291345; PubMed Central PMCID: PMC4040342.

34. Zhang L, Zhang JJ, Kubiak RJ, Yang H. Statistical methods and tool for cut point analysis in immunogenicity assays. J Immunol Methods. 2013;389(1–2):79–87. Epub 2013/01/12. doi: 10.1016/j.jim.2012.12.008 23305975.

35. Fauci AS, Marston HD. Ending AIDS—is an HIV vaccine necessary? N Engl J Med. 2014;370(6):495–8. doi: 10.1056/NEJMp1313771 24499210.

36. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556–60. Epub 2016/06/25. doi: 10.1038/nature18929 27338952; PubMed Central PMCID: PMC5034582.

37. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. Epub 2014/08/22. doi: 10.1128/JVI.02213-14 25142607; PubMed Central PMCID: PMC4248941.

38. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. doi: 10.1126/scitranslmed.3008992 24990883; PubMed Central PMCID: PMC4562469.

39. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016;533(7601):105–9. doi: 10.1038/nature17677 27120156; PubMed Central PMCID: PMC5127204.

40. Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs. 2017;9(5):792–800. Epub 2017/04/04. doi: 10.1080/19420862.2017.1311435 28368743; PubMed Central PMCID: PMC5524155.

41. Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med. 2017;14(11):e1002435. Epub 2017/11/15. doi: 10.1371/journal.pmed.1002435 29136037.

42. Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017;358(6359):85–90. doi: 10.1126/science.aan8630 28931639.